Pfizer's Lipitor-Torcetrapib Phase II Results Show HDL-LDL Double-Punch
This article was originally published in The Pink Sheet Daily
Executive Summary
Combination therapy trial reveals HDL-C increases of 61% for the drugs used together and 46% for torcetrapib alone. Pfizer is understood to be investing $800 mil. in the drug's development, including a $90 mil. manufacturing facility.
You may also be interested in...
Merck’s HDL-Raising Cholesterol Combo Has “Formulation Issues”
MK-0524B Phase III studies remain on track, the company maintains.
Merck’s HDL-Raising Cholesterol Combo Has “Formulation Issues”
MK-0524B Phase III studies remain on track, the company maintains.
Merck Unveils HDL-Cholesterol Drug Candidates
Phase III trials are starting for HDL-cholesterol therapy combining extended-release niacin and anti-flushing compound and for Zocor combination.